Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Itolizumab - Biocon/Equillium

X
Drug Profile

Itolizumab - Biocon/Equillium

Alternative Names: Alzumab-L; Anti-CD6 monoclonal antibody - Biocon/CIMAB; Anti-CD6 monoclonal antibody h-T1; Anti-CD6-monoclonal-antibody-Biocon; Bmab600; EQ-001; h T1; Humanised anti-CD6 monoclonal antibody ior t1; T12 antibody; T12 monoclonal antibody; T1h; T1hT

Latest Information Update: 03 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center of Molecular Immunology
  • Developer Biocon; Biotech Pharmaceutical; Equillium
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Urologics
  • Mechanism of Action CD6 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis
  • Registered Cytokine release syndrome; SARS-CoV-2 acute respiratory disease
  • Phase III Graft-versus-host disease
  • Phase II Ulcerative colitis
  • Phase I Lupus nephritis; Systemic lupus erythematosus
  • No development reported Asthma; Autoimmune disorders; Multiple sclerosis; Psoriasis
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 01 Apr 2024 Efficacy data from a phase Ib trial in Systemic lupus erythematosus released by Equillium
  • 18 Jan 2024 Equillium completes a phase Ib EQUALISE trial in Systemic lupus erythematosus and Lupus nephritis in Poland, India and USA (SC, injection) (NCT04128579)
  • 13 Nov 2023 Efficacy data from a phase Ib EQUALISE trial in Multiple sclerosis presented at the annual meeting of the American College of Rheumatology (ACR-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top